Vancomycin Peak Serum Concentration Monitoring: Implications for Homecare

Journal of Intravenous Nursing

Volumn 22, Issue 6, 1999, Pages 336-

  Tam, Vincent H ^a   Moore, Gail E ^b   Triller, Darren M ^c   Briceland, Laurie L ^c  

^a DETROIT RECEIVING HOSPITAL   (United States)

^b Russell Sage College   (United States)

^c ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ARTICLE; BACTERIAL INFECTION; DRUG BLOOD LEVEL; DRUG MONITORING; HOME CARE; HOME MONITORING; HUMAN;

ANTI-BACTERIAL AGENTS; COMMUNITY HEALTH NURSING; DRUG MONITORING; DRUG RESISTANCE, MICROBIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; HOME INFUSION THERAPY; HUMANS; VANCOMYCIN;

EID: 0033364527     PISSN: 08965846     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Fekety R. Vancomycin and teicoplanin. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 4th ed. New York: Churchill Livingstone, 1995: 346-54.
2. Rodvold KA, Blum RA, Fischer JH, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 1988; 32: 848-52.
3. Matzke GR, McGory RW, Halstenson CE, et al. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984; 24: 433-7.
4. Birt JK, Chandler MHH. Using clinical data to determine vancomycin dosing parameters. Ther Drug Monit 1990; 12: 206-9.
5. Rotschafer JC, Crossley K, Zaske DE, et al. Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother 1982; 22: 391-4.
6. Nielsen HE, Hansen HE, Korsager B, et al. Renal excretion of vancomycin in kidney disease. Acta Med Scand 1975; 197: 261-4.
7. Moellering RC, Krogstad DJ, Greenblatt DJ, et al. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 1981; 94: 343-6.
8. Peetermans WE, Hoogeterp JJ, Hazekamp-Van Dokkum AM, et al. Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection. Antimicrob Agents Chemother 1990; 34: 1869-74.
9. Ackerman BH, Vannier AM, Eudy EB. Analysis of vancomycin time-kill studies with staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response. Antimicrob Agents Chemother 1992; 36: 1766-9.
10. Löwdin E, Odenholt I, Cars O. In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1998; 42: 2739-44.
11. Ferraro MJ, Craig WA, Dudley MN, et al. Performance standards for antimicrobial susceptibility testing. Ninth informational supplement. Wayne, PA: National Committee for Clinical Laboratory Standards, 1999.
12. Fitzsimmons WE, Postelnick MJ, Tortorice PV. Survey of vancomycin monitoring guidelines in Illinois hospitals. Drug Intell Clin Pharm 1988; 22: 598-600.
13. Perino LM, Mueller BA. Accuracy of vancomycin serum concentrations in patients with renal failure. Ann Pharmacother 1993; 27): 892-3.
14. Farber BF, Moellering RC. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983; 23: 138-41.
15. Rybak MJ, Albrecht LM, Boike SC, et al. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990; 25: 679-87.
16. Pauly DJ, Musa DM, Lestico MR, et al. Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy. Pharmacotherapy 1990; 10: 378-82.
17. Sorrell TC, Collignon PJ. A prospective study of adverse reactions associated with vancomycin therapy. J Antimicrob Chemother 1985; 16: 235-41.
18. Goetz MB, Sayers J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J Antimicrob Chemother 1993; 32: 325-34.
19. Brummett RE, Fox KE. Vancomycin- and erythromycin-induced hearing loss in humans. Antimicrob Agents Chemother 1989; 33: 791-6.
20. Brummett RE, Fox KE, Jacobs F, et al. Augmented gentamicin ototoxicity induced by vancomycin in guinea pigs. Arch Otolaryngol Head Neck Surg 1990; 116: 61-4.
21. Lake KD, Peterson CD. A simplified dosing method for initiating vancomycin therapy. Pharmacotherapy 1985; 5: 340-4.
22. Brown DL, Mauro LS. Vancomycin dosing chart for use in patients with renal impairment. Am J Kidney Dis 1988; 11: 15-9.
23. Matzke GR, Kovarik JM, Rybak MJ, et al. Evaluation of the vancomycin-clearance: creatinine clearance relationship for predicting vancomycin dosage. Clin Pharm 1985; 4: 311-5.
24. Rybak MJ, Boike SC. Individualized adjustment of vancomycin dosage: comparison with two dosage nomograms. Drug Intell Clin Pharm 1986; 20: 64-8.
25. Pryka RD, Rodvold KA, Erdman SM. An update comparison of drug dosing methods. Part IV: vancomycin. Clin Pharmacokinet 1991; 20: 463-76.
26. Edwards DJ, Pancorbo S. Routine monitoring of serum vancomycin concentrations: waiting for proof of its value. Clin Pharm 1987; 6: 652-4.
27. Freeman CD, Quintiliani R, Nightingale CH. Vancomycin therapeutic drug monitoring: is it necessary? Ann Pharmacother 1993; 27: 594-8.
28. Cantú TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 1994; 18: 533-43.
29. Leader WG, Chandler MHH, Castiglia M. Pharmacokinetic optimisation of vancomycin therapy. Clin Pharmacokinet 1995; 28: 327-42.
30. Rodvold KA, Zokufa H, Rotschafer JC. Routine monitoring of serum vancomycin concentrations: can waiting be justified? Clin Pharm 1987; 6: 655-8.
31. Moellering RC. Monitoring serum vancomycin levels: climbing the mountain because it is there? (Editorial). Clin Infect Dis 1994; 18: 544-6.
32. Saunders NJ. Why monitor peak vancomycin concentrations? Lancet 1994; 344: 1748-50.
33. Karam CM, McKinnon PS, Neuhauser MM, et al. Outcome assessment of minimizing vancomycin monitoring and dosing adjustments. Pharmacotherapy 1999; 19: 257-66.